A response to “Male balding is a major risk factor for severe COVID-19” - 11/01/21
Doi : 10.1016/j.jaad.2020.10.051
Akshitha Thatiparthi, BS a, Jeffrey Liu, BS b, Amylee Martin, BS c, Jashin J. Wu, MD d, ⁎ 
a College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA
b Keck School of Medicine, University of Southern California, Los Angeles, CA
c School of Medicine, University of California, Riverside, CA
d Dermatology Research and Education Foundation, Irvine, CA
∗Correspondence to: Jashin J. Wu, MD, Dermatology Research and Education Foundation, Irvine, CA 92620Dermatology Research and Education FoundationIrvineCA92620
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Dr. Reddy's Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, and Valeant Pharmaceuticals North America LLC. The rest of the authors have no conflicts to disclose. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 2
P. e87-e88 - février 2021 Retour au numéro
Article précédent
- Panoramic trichoscopy
- Leonardo Spagnol Abraham, Sofia Sales Martins, Rodrigo Pirmez, Bruna Duque-Estrada
- Reply to letter to the editor: “A response to ‘Male balding is a major risk factor for severe COVID-19’”
- Ahmed Yousaf, Michael S. Kolodney
Bienvenue sur EM-consulte, la référence des professionnels de santé.